Info

🌱 來自: Molecular biology-of-NSCLC

KRAS Mt

• 25% of ADCL (Cancer Discov 2017;7:596; CCR 2018;24:1038), a/w smoking (transversions: G12C 40% of KRAS Mt, G12V) but present in 4% of never-smokers (transitions: G12D).
• Confers worse prog.
• KRAS G12C specific inhibitor available.
• Targetable driver oncogenes are generally mutually exclusive in tx-naïve tumors